NASDAQ NMS - GLOBAL MARKET · ELTX
-0.33% · -$0.0100 · Vol Not reported
Pre-market · updated 05:16:49 ET
Elicio Therapeutics Inc

Elicio Therapeutics Inc

Biotechnology
$3.03
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Analyst data unavailable at compute time
ELTX
Elicio Therapeutics Inc
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
AVOID

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

15/ 100
Veridion Score
AVOID · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ELTX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ELTX catalysts
About Elicio Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2023
Employees
33
Country
US

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.04
Last session
Day high
$3.04
Last session
Day low
$3.04
Last session
Previous close
$3.04
52W high
$14.85
-79.60% from high
52W low
$2.76
2% of range
Market cap
$79.9M
EPS
$-2.3400
Beta
-3.51
Shares out
26.3M
Avg volume
344.4K
VWAP
$3.04
Last session
Price history computed in-house
1W
+0.33%
1M
+1.00%
3M
-69.79%
1Y
-74.32%
YTD
-61.93%
SMA 50 $3.78 · below
SMA 200 $8.33 · below
52W position 2%

ELTX overview

Veridion Score
15
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ELTX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ELTX Form 4 filings
Public disclosures

Congress activity in ELTX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ELTX in the cached public ledger.

Federal contracts

ELTX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ELTX in this window.
Lobbying spend

ELTX lobbying filings, year to date.

Registered lobbying filings matched to Elicio Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ELTX in this window.
Loading news for ELTX
Analyst ratings
Sovereign unlock shows live analyst consensus for ELTX.
Options
Sovereign unlock shows live options positioning for ELTX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.